Table 3.
Drug-induced acute pancreatitis causative drugs (number of hospitalizations) classified according to the evidence-level classification system proposed by Badalov and colleagues [12] (n = 90).
| Class Iaa | Class Ibb | Class IIc | Class IIId | Class IVe | |
|---|---|---|---|---|---|
| 5-Fluorouracil (2) | N/A | Azathioprine (7) | Amoxicillin–clavulanic acid ∗ (2) | Azithromycin | Lurasidone |
| Atorvastatin (6) | Codeine (4) | Cisplatin (3) | Canagliflozin | Metformin | |
| Bortezomib (2) | Hydrochlorothiazide (5) | Dexamethasone (2) | Capecitabine | Methotrexate | |
| Nilotinib (2) | Mercaptopurine (3) | Carbamazepine | Metronidazole | ||
| Rosuvastatin (4) | Mesalazine (3) | Celecoxib | Minocycline | ||
| Triamcinolone (3) | Saxagliptin (2) | Certolizumab | Morphine | ||
| Sitagliptin (2) | Clarithromycin | Naproxen | |||
| Sitagliptin–metformin ∗ (2) | Clindamycin | Pazopanib | |||
| Trimethoprim–sulfamethoxazole∗(2) | Cyclophosphamide-doxorubicin∗ | Perindopril | |||
| Venlafaxine (2) | Cyclophosphamide-vincristine-doxorubicin∗ | Phenytoin | |||
| Diclofenac | Rifampin | ||||
| Ezetimibe | Saxagliptin-metformin ∗ | ||||
| Ibuprofen | Sertraline | ||||
| Immediate-release morphine | Simvastatin sulfasalazine | ||||
| Losartan/hydrochlorothiazide∗ | Tamoxifen | ||||
| Tocilizumab | |||||
aClass Ia included drugs for which at least one case of rechallenge has been described and all potential causes of acute pancreatitis have been excluded. bClass Ib included drugs for which at least one case of rechallenge has been described and the potential causes of acute pancreatitis have not been excluded. cClass II included drugs found in at least four evidences. dClass III included drugs found in at least two evidences. eClass IV included drugs found in at least one evidence. Each individual medication included in this class was implicated in only 1 case. The asterisk (∗) means that the drugs are in association. The drugs in bold are not present in the systematic review of Badalov et al. (2007).